More frequent surveillance not linked to longer recurrence-free, overall survival in pathologic stage I non-small cell lung cancer

However, screening of high-risk individuals for lung cancer is still low at 5.8 percent nationally

Approval is for tremelimumab in combination with durvalumab and platinum-based chemotherapy

More than 50 cancer groups have issued an urgent call for more lung cancer screening among high-risk people

Only 22.3 percent of those with an initial LDCT had a repeat annual LDCT; 34.3 percent adherent with follow-up to 24 months

New long-term opioid use associated with increased risk for two-year all-cause mortality, especially for potent opioid use

Reduced segmentation time, interobserver variability seen with artificial intelligence assistance in segmentation for radiotherapy targeting

About 15 percent of patients diagnosed with lung cancer had PGVs, most of which were potentially clinically actionable

Drug approved for non-small cell lung cancer with mutation leading to MET exon 14 skipping

Little or no interest in sexual activity reported by majority of patients surveyed